A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H6: PF-07304814)
Latest Information Update: 10 May 2024
Price :
$35 *
At a glance
- Drugs Lufotrelvir (Primary) ; Remdesivir
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms ACTIV-3/TICO; Trial H6: PF-07304814
- Sponsors Pfizer
- 07 Feb 2024 Status changed from suspended to discontinued.
- 20 Mar 2023 Status changed from recruiting to suspended.
- 08 Dec 2021 Status changed from planning to recruiting, according to a Pfizer company pipeline.